Abstract Library

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#4413 Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia (APSIN) – A multi-centre, prospective, randomised, controlled, phase III study

Introduction: Our multi-centre, prospective, open-label, two-arm parallel group, randomised, controlled, phase III study will address the efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia.

Conference:

Presenting Author: Eilsberger F

Authors: Eilsberger F, Luster M, Rau J, Avci H, Schade-Brittinger C,

Keywords: adjuvant therapy, neuroendocrine neoplasia, small intestine, peptide receptor radionuclide therapy, PRRT,

#4321 Insulinoma – A diagnostic challenge

Introduction: Insulinomas are rare pancreatic neuroendocrine neoplasms (pNEN). Operative resection is the treatment of choice.

Conference:

Presenting Author:

Authors: Ritter A, Poppinga J, Steinkraus K, von Kroge P, Amin T,

Keywords: Neuroendocrine neoplasia, insulinoma, pancreatic NEN, hypoglycaemia,